Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ARC_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ARC_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/ARC_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ARC_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:200005933 | Oral cavity | NEOLP | negative regulation of ubiquitin-dependent protein catabolic process | 14/2005 | 48/18723 | 3.56e-04 | 3.41e-03 | 14 |
GO:003030821 | Oral cavity | NEOLP | negative regulation of cell growth | 36/2005 | 188/18723 | 3.88e-04 | 3.63e-03 | 36 |
GO:000974325 | Oral cavity | NEOLP | response to carbohydrate | 45/2005 | 253/18723 | 4.43e-04 | 4.00e-03 | 45 |
GO:003428425 | Oral cavity | NEOLP | response to monosaccharide | 41/2005 | 225/18723 | 4.69e-04 | 4.20e-03 | 41 |
GO:006161431 | Oral cavity | NEOLP | pri-miRNA transcription by RNA polymerase II | 15/2005 | 55/18723 | 4.94e-04 | 4.39e-03 | 15 |
GO:003052123 | Oral cavity | NEOLP | androgen receptor signaling pathway | 13/2005 | 44/18723 | 4.99e-04 | 4.42e-03 | 13 |
GO:00069973 | Oral cavity | NEOLP | nucleus organization | 27/2005 | 133/18723 | 7.89e-04 | 6.27e-03 | 27 |
GO:005109121 | Oral cavity | NEOLP | positive regulation of DNA-binding transcription factor activity | 45/2005 | 260/18723 | 8.06e-04 | 6.39e-03 | 45 |
GO:004217732 | Oral cavity | NEOLP | negative regulation of protein catabolic process | 25/2005 | 121/18723 | 9.29e-04 | 7.20e-03 | 25 |
GO:000974624 | Oral cavity | NEOLP | response to hexose | 39/2005 | 219/18723 | 1.00e-03 | 7.68e-03 | 39 |
GO:007132223 | Oral cavity | NEOLP | cellular response to carbohydrate stimulus | 31/2005 | 163/18723 | 1.07e-03 | 8.08e-03 | 31 |
GO:190289531 | Oral cavity | NEOLP | positive regulation of pri-miRNA transcription by RNA polymerase II | 12/2005 | 42/18723 | 1.13e-03 | 8.46e-03 | 12 |
GO:190289331 | Oral cavity | NEOLP | regulation of pri-miRNA transcription by RNA polymerase II | 14/2005 | 54/18723 | 1.30e-03 | 9.43e-03 | 14 |
GO:007133323 | Oral cavity | NEOLP | cellular response to glucose stimulus | 29/2005 | 151/18723 | 1.30e-03 | 9.44e-03 | 29 |
GO:000167824 | Oral cavity | NEOLP | cellular glucose homeostasis | 32/2005 | 172/18723 | 1.31e-03 | 9.48e-03 | 32 |
GO:007133123 | Oral cavity | NEOLP | cellular response to hexose stimulus | 29/2005 | 153/18723 | 1.60e-03 | 1.12e-02 | 29 |
GO:007132623 | Oral cavity | NEOLP | cellular response to monosaccharide stimulus | 29/2005 | 154/18723 | 1.78e-03 | 1.22e-02 | 29 |
GO:001908321 | Oral cavity | NEOLP | viral transcription | 13/2005 | 50/18723 | 1.85e-03 | 1.27e-02 | 13 |
GO:003085021 | Oral cavity | NEOLP | prostate gland development | 12/2005 | 45/18723 | 2.17e-03 | 1.42e-02 | 12 |
GO:000828622 | Oral cavity | NEOLP | insulin receptor signaling pathway | 23/2005 | 116/18723 | 2.56e-03 | 1.61e-02 | 23 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ARC | SNV | Missense_Mutation | | c.373N>T | p.Arg125Cys | p.R125C | Q7LC44 | protein_coding | deleterious_low_confidence(0) | benign(0.432) | TCGA-A1-A0SG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | | SD |
ARC | SNV | Missense_Mutation | rs766434970 | c.1144N>A | p.Ala382Thr | p.A382T | Q7LC44 | protein_coding | deleterious_low_confidence(0.01) | benign(0.026) | TCGA-LL-A7T0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ARC | SNV | Missense_Mutation | | c.932N>T | p.Thr311Met | p.T311M | Q7LC44 | protein_coding | deleterious(0.05) | probably_damaging(0.933) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ARC | SNV | Missense_Mutation | | c.686G>A | p.Arg229Gln | p.R229Q | Q7LC44 | protein_coding | tolerated(0.18) | benign(0.015) | TCGA-AA-3494-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folinic | PR |
ARC | SNV | Missense_Mutation | novel | c.365N>A | p.Arg122His | p.R122H | Q7LC44 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.991) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ARC | SNV | Missense_Mutation | rs771620864 | c.307G>A | p.Ala103Thr | p.A103T | Q7LC44 | protein_coding | deleterious_low_confidence(0.02) | possibly_damaging(0.649) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
ARC | SNV | Missense_Mutation | | c.1043N>G | p.Leu348Arg | p.L348R | Q7LC44 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AD-A5EJ-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ARC | SNV | Missense_Mutation | rs771620864 | c.307N>A | p.Ala103Thr | p.A103T | Q7LC44 | protein_coding | deleterious_low_confidence(0.02) | possibly_damaging(0.649) | TCGA-AU-6004-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ARC | SNV | Missense_Mutation | rs774341447 | c.332N>A | p.Arg111His | p.R111H | Q7LC44 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.994) | TCGA-CM-6165-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
ARC | SNV | Missense_Mutation | | c.1111N>T | p.Pro371Ser | p.P371S | Q7LC44 | protein_coding | deleterious_low_confidence(0.02) | benign(0.001) | TCGA-D5-6929-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | oxaliplatinum+ | SD |